Additional file 5: Figure S1. High level workflow for ICI biomarker validation and combination. The N biomarkers were individually tested for each dataset, this test serving as a primary validation of the proposed performance. Mean accuracy was computed for each classifier in all available datasets. Combinatorial analysis was carried out with majority voting and Generalized Linear Models. The E[X] formula stands as an example of the model to create when estimating the a0âŚaN linear factors
Additional file 1: Table S1. Detectable fold-changes (FC) at 80% power between toxicity groups for t...
Immune checkpoint inhibitors have revolutionized treatment of advanced melanoma, but commonly cause ...
Immune checkpoint inhibitors (ICI) have been applied in treating advanced hepatocellular carcinoma (...
Additional file 7: Table S5. Summary of the biomarker performance. The second column indicates the n...
Additional file 11: Table S9. GLM coefficient estimates, with their respective standard errors, t-va...
Additional file 10: Table S8. Marker frequencies in the previous combinations with AUC greater than ...
Additional file 2: Table S1. Separation criteria for responder and non-responder groups in the datas...
Abstract Background There are no accepted universal biomarkers capable to accurately predict respons...
Additional file 4: Table S3. Per-patient summary of clinical classification where both DNA and RNA d...
The development of molecular signatures for the prediction of time-to-event outcomes is a methodolog...
In order to improve anti-cancer treatment, we need to better understand why some patients respond to...
Immunotherapeutic agents have shown impressive clinical efficacy in a broad range of tumour types, p...
The development of molecular signatures for the prediction of time-to-event outcomes is a methodolog...
Abstract Background Immune checkpoint inhibitors have...
The development of molecular signatures for the prediction of time-to-event outcomes is a methodolog...
Additional file 1: Table S1. Detectable fold-changes (FC) at 80% power between toxicity groups for t...
Immune checkpoint inhibitors have revolutionized treatment of advanced melanoma, but commonly cause ...
Immune checkpoint inhibitors (ICI) have been applied in treating advanced hepatocellular carcinoma (...
Additional file 7: Table S5. Summary of the biomarker performance. The second column indicates the n...
Additional file 11: Table S9. GLM coefficient estimates, with their respective standard errors, t-va...
Additional file 10: Table S8. Marker frequencies in the previous combinations with AUC greater than ...
Additional file 2: Table S1. Separation criteria for responder and non-responder groups in the datas...
Abstract Background There are no accepted universal biomarkers capable to accurately predict respons...
Additional file 4: Table S3. Per-patient summary of clinical classification where both DNA and RNA d...
The development of molecular signatures for the prediction of time-to-event outcomes is a methodolog...
In order to improve anti-cancer treatment, we need to better understand why some patients respond to...
Immunotherapeutic agents have shown impressive clinical efficacy in a broad range of tumour types, p...
The development of molecular signatures for the prediction of time-to-event outcomes is a methodolog...
Abstract Background Immune checkpoint inhibitors have...
The development of molecular signatures for the prediction of time-to-event outcomes is a methodolog...
Additional file 1: Table S1. Detectable fold-changes (FC) at 80% power between toxicity groups for t...
Immune checkpoint inhibitors have revolutionized treatment of advanced melanoma, but commonly cause ...
Immune checkpoint inhibitors (ICI) have been applied in treating advanced hepatocellular carcinoma (...